Nonmelanoma Skin Cancer – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of nonmelanoma skin cancer comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of basal and squamous cell carcinoma for each country, as well as annualized case counts projected to the national population.

In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in the first line of therapy.

Clarivate Epidemiology’s basal and squamous cell carcinoma forecast will answer the following question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of basal and squamous cell carcinoma over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology provides at least 10 years of forecast data for the following:

  • Total number of cases of basal and squamous cell carcinoma for each forecast year.
  • Diagnosed incident cases of basal and squamous cell carcinoma.
  • Diagnosed incident cases of basal and squamous cell carcinoma (nonmetastatic and metastatic) by stage.
  • Recurrent incident cases of basal and squamous cell carcinoma.
  • Diagnosed prevalent cases of basal and squamous cell carcinoma.
  • First-line drug-treatable cases of basal and squamous cell carcinoma.
  • … and more (details available on request).

Note: Coverage may vary by country.